DK1631291T3 - Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes - Google Patents

Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes

Info

Publication number
DK1631291T3
DK1631291T3 DK04739375T DK04739375T DK1631291T3 DK 1631291 T3 DK1631291 T3 DK 1631291T3 DK 04739375 T DK04739375 T DK 04739375T DK 04739375 T DK04739375 T DK 04739375T DK 1631291 T3 DK1631291 T3 DK 1631291T3
Authority
DK
Denmark
Prior art keywords
tyrosine kinase
kinase inhibitors
diabetes
treat diabetes
type
Prior art date
Application number
DK04739375T
Other languages
Danish (da)
English (en)
Inventor
Robert P Haegerkvist
Nils Richard Welsh
Original Assignee
Robert P Haegerkvist
Nils Richard Welsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312086A external-priority patent/GB0312086D0/en
Priority claimed from GB0402682A external-priority patent/GB0402682D0/en
Application filed by Robert P Haegerkvist, Nils Richard Welsh filed Critical Robert P Haegerkvist
Application granted granted Critical
Publication of DK1631291T3 publication Critical patent/DK1631291T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK04739375T 2003-05-27 2004-05-26 Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes DK1631291T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312086A GB0312086D0 (en) 2003-05-27 2003-05-27 Organic compounds
GB0402682A GB0402682D0 (en) 2004-02-06 2004-02-06 Organic compounds
PCT/EP2004/005679 WO2004105763A2 (fr) 2003-05-27 2004-05-26 Utilisation d'un inhibiteur de tyrosine kinase c-abl-, pdgf-r- ou c-kit- dans le traitement du diabete

Publications (1)

Publication Number Publication Date
DK1631291T3 true DK1631291T3 (da) 2009-11-02

Family

ID=33492240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04739375T DK1631291T3 (da) 2003-05-27 2004-05-26 Anvendelse af tyrosinkinaseinhibitorer til behandling af diabetes

Country Status (21)

Country Link
US (1) US7875616B2 (fr)
EP (1) EP1631291B1 (fr)
JP (1) JP4776537B2 (fr)
KR (1) KR101102229B1 (fr)
AT (1) ATE439133T1 (fr)
BR (1) BRPI0410704A (fr)
CA (1) CA2526594C (fr)
DE (1) DE602004022540D1 (fr)
DK (1) DK1631291T3 (fr)
ES (1) ES2331800T3 (fr)
HK (1) HK1087638A1 (fr)
IL (1) IL171927A (fr)
IS (1) IS2712B (fr)
MA (1) MA27812A1 (fr)
MX (1) MXPA05012739A (fr)
NO (1) NO331715B1 (fr)
NZ (1) NZ543709A (fr)
PL (1) PL1631291T3 (fr)
PT (1) PT1631291E (fr)
RU (1) RU2365373C2 (fr)
WO (1) WO2004105763A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653934B1 (fr) * 2003-08-15 2008-05-14 AB Science Utilisation d'inhibiteurs de c-kit pour le traitement du diabete de type ii
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US20120329794A1 (en) * 2006-06-30 2012-12-27 Kyowa Hakko Kirin Co., Ltd. Ab1 KINASE INHIBITORS
IN2014DN02060A (fr) * 2011-09-15 2015-05-15 Novartis Ag

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
EP0773313B1 (fr) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Ceintures de sécurité résistants à la flamme contenant des fibres de polyester modifiées par du phosphore
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ES2234523T3 (es) * 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
WO2001060363A1 (fr) * 2000-02-15 2001-08-23 Teva Pharmaceutical Industries Ltd. Procede permettant d'effectuer la synthese du leflunomide
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
AR035721A1 (es) * 2000-12-20 2004-07-07 Sugen Inc Indolinonas 4-aril sustituidas; sus composiciones farmaceuticas y metodo para modular la actividad catalitica de una proteina quinasa
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AUPS243002A0 (en) 2002-05-20 2002-06-13 Baker Medical Research Institute Therapeutic target and uses thereof
DE10235227A1 (de) * 2002-08-01 2004-02-19 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes
EP1576129A4 (fr) 2002-08-09 2008-01-23 Theravance Inc Polypeptides de fusion d'oncokinase associes a des troubles hyperproliferatifs, acides nucleiques codant pour lesdits polypeptides et leurs methodes de detection et d'identification
WO2004043408A2 (fr) 2002-11-13 2004-05-27 Genpath Pharmaceuticals, Incorporated Gpc15 : methodes et compositions pour le traitement du cancer
DE10255360A1 (de) * 2002-11-27 2004-06-17 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes

Also Published As

Publication number Publication date
KR20060021865A (ko) 2006-03-08
JP2006528225A (ja) 2006-12-14
CA2526594C (fr) 2011-11-08
US7875616B2 (en) 2011-01-25
ES2331800T3 (es) 2010-01-15
BRPI0410704A (pt) 2006-06-13
ATE439133T1 (de) 2009-08-15
DE602004022540D1 (de) 2009-09-24
NO20056188L (no) 2005-12-23
CA2526594A1 (fr) 2004-12-09
NO331715B1 (no) 2012-03-05
PT1631291E (pt) 2009-10-28
RU2365373C2 (ru) 2009-08-27
KR101102229B1 (ko) 2012-01-05
WO2004105763A2 (fr) 2004-12-09
EP1631291A2 (fr) 2006-03-08
RU2005140516A (ru) 2007-07-10
PL1631291T3 (pl) 2010-04-30
WO2004105763A3 (fr) 2005-06-02
IL171927A0 (en) 2006-04-10
MXPA05012739A (es) 2006-05-17
HK1087638A1 (en) 2006-10-20
IS2712B (is) 2011-01-15
IS8139A (is) 2005-11-22
AU2004243491A1 (en) 2004-12-09
IL171927A (en) 2011-10-31
MA27812A1 (fr) 2006-03-01
EP1631291B1 (fr) 2009-08-12
NZ543709A (en) 2009-04-30
JP4776537B2 (ja) 2011-09-21
US20070072932A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
DK1585743T3 (da) 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
IS8139A (is) Notkun týrósínkínasatálma til að meðhöndla sykursýki
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
EA200600829A1 (ru) Новые кристаллические формы {2-[1-(3,5-бистрифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]-пиридин-3-ил}-(2-хлорфенил)метанона
DE602007011756D1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
ATE399555T1 (de) Behandlung der rheumatoiden arthritis mit imitanib
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
DE602005025514D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
WO2006012958A3 (fr) Combinaison comprenant un inhibiteur bcrp et 4-(4-methylpiperazine-1-ylmethyle)-n-[4-methyl-3-(4-pyridine-3-yl)pyrimidine-2-ylamino)phenyle]-benzamide
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
WO2004026930A3 (fr) Composes organiques
UY28498A1 (es) Modificación de cristal de un derivado de n-fenil-2-pirimidinamina, procesos para su fabricación y su uso.